This Week in Cell

An international team led by René Bernards, with The Netherlands Cancer Institute and Agendia, explores the genetics of cancer treatment susceptibility and resistance, focusing first on ALK and EGF receptor tyrosine kinase inhibitor therapies. Using an RNA interference screen in a non-small cell lung cancer line carrying an EML4-ALK translocation, the researchers determined that knocking down a gene called MED12 confers resistance to an ALK-inhibiting drug called crizotinib.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.